SPDL1 and non-small cell lung carcinoma: In another study, patients with NSCLC who responded to nivolumab treatment had lower levels of sPD-L1 3 months after treatment compared to non-responders (Fig. 3C), and low sPD-L1 was correlated with longer PFS (Fig. 3D) [90].